Organon Completes Agreement to License MIUDELLA®, Sebela Pharmaceuticals’ Hormone-Free Intrauterine Device
Organon completed a global licensing agreement with Sebela Pharmaceuticals for MIUDELLA, the first hormone-free copper intrauterine device (IUD) introduced in the US in over 40 years. Approved by the FDA in February 2025, MIUDELLA is 99% effective over three years and features proprietary SLIMSERT technology designed for easier insertion.
Key figures
- Drug Name
- MIUDELLA
- Efficacy
- 99%
- Pearl index year 1
- 0.94
- Pearl index year 3
- 1.05
- Trial participants
- 1904
- Placement success rate
- 98.8%
- Insertion tube diameter mm
- 3.7
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.